SCHEMBL7118702

SCHEMBL7118702

NC(=O)c1ccc(-c2ccc(Cl)cc2)o1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.69
LMNA P02545 3/20 0.69
HPGD P15428 3/20 0.69
KDM4E B2RXH2 2/20 0.69
PRNP P04156 1/20 0.69
HSD17B10 Q99714 1/20 0.69
SLC9A1 P19634 1/20 0.69
ERCC5 P28715 1/20 0.58
FEN1 P39748 1/20 0.58
PTPN1 P18031 1/20 0.55
ALOX12 P18054 1/20 0.54
SCN5A Q14524 1/20 0.54
SCN2A Q99250 1/20 0.54
SCN10A Q9Y5Y9 1/20 0.54
NPC1 O15118 4/20 0.52
RAB9A P51151 4/20 0.52
PDE4B Q07343 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
MAPT P10636 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11826852 0.85 ALDH1A1 (0.63) ALDH1A1LMNAHPGDKDM4ESLC9A1
SCHEMBL1286218 0.83 ALDH1A1 (0.70) ALDH1A1LMNAHPGDKDM4ESLC9A1
SCHEMBL2031645 0.83 ALDH1A1 (0.71) ALDH1A1LMNAHPGDKDM4EPRNP
SCHEMBL3325905 0.83 ALDH1A1 (0.61) ALDH1A1LMNAHPGDKDM4ESLC9A1
SCHEMBL9478990 0.82 ERCC5 (0.71) ALDH1A1LMNAHPGDKDM4ESLC9A1
SCHEMBL4944134 0.82 SLC9A1 (1.00) SLC9A1
SCHEMBL12885825 0.81 ALDH1A1 (0.69) ALDH1A1LMNAHPGDKDM4EPRNP
SCHEMBL9477782 0.81 ALDH1A1 (0.69) ALDH1A1LMNAHPGDSLC9A1ERCC5
SCHEMBL15218337 0.81 ALDH1A1 (0.69) ALDH1A1LMNAHPGDKDM4EPRNP
SCHEMBL4163540 0.81 ALDH1A1 (0.68) ALDH1A1LMNAHPGDKDM4EPRNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100345847-C Novel biarylcarboxamides ASTRAZENECA AB (SE) 2007-10-31 CN claimed
CN-1400973-A Novel biarylcarboxamides ASTRAZENECA AB (SE) 2003-03-05 CN claimed
EP-4596548-A1 NURR1 MODULATORS Ludwig-Maximilians-Universität (DE) 2025-08-06 EP disclosed
EP-2512238-B1 FUSED TRICYCLIC COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME (US) 2014-06-25 EP disclosed
CN-100345847-C Novel biarylcarboxamides ASTRAZENECA AB (SE) 2007-10-31 CN disclosed
CN-1400973-A Novel biarylcarboxamides ASTRAZENECA AB (SE) 2003-03-05 CN disclosed
US-20030008867-A1 Compounds ASTRAZENECA AB (SE) 2003-01-09 US disclosed
US-5214042-A Use of 5-phenyl-2-furan esters, amides and ketones as neuroprotective agents NORWICH EATON PHARMACEUTICALS, INC. (US) 1993-05-25 US disclosed
US-5118708-A USE OF 5-PHENYL-2-FURAN ESTERS, AMIDES AND KETONES AS NEUROPROTECTIVE AGENTS NORWICH EATON PHARMACEUTICALS, INC. (US) 1992-06-02 US disclosed
US-5023272-A Use of 5-phenyl-2-furan esters and amides as antiepileptic agents NORWICH EATON PHARMACEUTICALS, INC. (US) 1991-06-11 US disclosed
EP-0404231-A1 The use of 5-phenyl-2 furan esters and amides as antiepileptic agents Norwich Eaton Pharmaceuticals, Inc. (US) 1990-12-27 EP disclosed
EP-0404233-A2 Novel use of 5-phenyl-2-furan esters, amides and ketones as neuroprotective agents Norwich Eaton Pharmaceuticals, Inc. (US) 1990-12-27 EP disclosed
US-4066668-A 5-(4-CHLOROPHENYL)-2-FURIMIDIC ACID HYDRAZIDES MORTON-NORWICH PRODUCTS, INC. (US) 1978-01-03 US disclosed
US-4066668-A 5-(4-CHLOROPHENYL)-2-FURIMIDIC ACID HYDRAZIDES MORTON-NORWICH PRODUCTS, INC. (US) 1978-01-03 US disclosed
US-4066668-A 5-(4-CHLOROPHENYL)-2-FURIMIDIC ACID HYDRAZIDES MORTON-NORWICH PRODUCTS, INC. (US) 1978-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030008867-A1 Compounds DRD2, DRD1, GRIN2A ALDH1A1 75/4885LMNA 1991/4885HPGD 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.